{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:27:16Z","timestamp":1793672836224,"version":"4.5.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10072-026-09430-5","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T06:37:29Z","timestamp":1790923049000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence, severity, and associated risk factors for amyloid-related imaging abnormalities in anti-amyloid monoclonal antibody therapy for early Alzheimer's disease: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6516-6975","authenticated-orcid":false,"given":"Markus A.","family":"Martinez Holst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9532-6866","authenticated-orcid":false,"given":"Ana Maria","family":"Sierra Valiente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2838-6251","authenticated-orcid":false,"given":"Carlos A.","family":"Garcia-Becerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"issue":"2","key":"9430_CR1","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/alz.12694","volume":"19","author":"A Gustavsson","year":"2023","unstructured":"Gustavsson A et al (2023) Global estimates on the number of persons across the Alzheimer\u2019s disease continuum. Alzheimer\u2019s Dementia: J Alzheimer\u2019s Assoc 19(2):658\u2013670. https:\/\/doi.org\/10.1002\/alz.12694","journal-title":"Alzheimer's Dementia: J Alzheimer's Assoc"},{"key":"9430_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2025.102990","volume":"114","author":"PS Baviskar","year":"2026","unstructured":"Baviskar PS, Mahajan HS (2026) Unveiling Alzheimer\u2019s disease (1901-2025): historical insights, global burden, biological mechanisms, diagnostics, and therapeutic strategies. Ageing Res Rev 114:102990. https:\/\/doi.org\/10.1016\/j.arr.2025.102990","journal-title":"Ageing Res Rev"},{"issue":"10","key":"9430_CR3","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00415-025-13456-8","volume":"272","author":"X Guo","year":"2025","unstructured":"Guo X et al (2025) Advances of therapeutic strategies for Alzheimer\u2019s disease. J Neurol 272(10):705. https:\/\/doi.org\/10.1007\/s00415-025-13456-8","journal-title":"J Neurol"},{"issue":"10510","key":"9430_CR4","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1016\/S0140-6736(25)01329-7","volume":"406","author":"NC Fox","year":"2025","unstructured":"Fox NC et al (2025) Treatment for Alzheimer\u2019s disease. Lancet 406(10510):1408\u20131423. https:\/\/doi.org\/10.1016\/S0140-6736(25)01329-7","journal-title":"Lancet"},{"issue":"3","key":"9430_CR5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","volume":"79","author":"M Filippi","year":"2022","unstructured":"Filippi M et al (2022) Amyloid-related imaging abnormalities and \u03b2-amyloid-targeting antibodies: a systematic review. JAMA Neurol 79(3):291\u2013304. https:\/\/doi.org\/10.1001\/jamaneurol.2021.5205","journal-title":"JAMA Neurol"},{"issue":"5S","key":"9430_CR6","doi-asserted-by":"publisher","first-page":"S202","DOI":"10.1016\/j.jacr.2025.02.031","volume":"22","author":"Expert Panel on Neurological Imaging","year":"2025","unstructured":"Expert Panel on Neurological Imaging et al (2025) ACR appropriateness criteria\u00ae dementia: 2024 update. J Am Coll Radiol 22(5S):S202\u2013S233. https:\/\/doi.org\/10.1016\/j.jacr.2025.02.031","journal-title":"J Am Coll Radiol"},{"issue":"11","key":"9430_CR7","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel H et al (2023) Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain 146(11):4414\u20134424. https:\/\/doi.org\/10.1093\/brain\/awad188","journal-title":"Brain"},{"issue":"19","key":"9430_CR8","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1212\/WNL.0000000000207757","volume":"101","author":"VK Ramanan","year":"2023","unstructured":"Ramanan VK et al (2023) Antiamyloid monoclonal antibody therapy for Alzheimer disease: emerging issues in neurology. Neurology 101(19):842\u2013852. https:\/\/doi.org\/10.1212\/WNL.0000000000207757","journal-title":"Neurology"},{"issue":"12","key":"9430_CR9","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","volume":"389","author":"RA Sperling","year":"2023","unstructured":"Sperling RA et al (2023) Trial of Solanezumab in Preclinical Alzheimer\u2019s disease. New England J Med 389(12):1096\u20131107. https:\/\/doi.org\/10.1056\/NEJMoa2305032","journal-title":"New England J Med"},{"issue":"2","key":"9430_CR10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S et al (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis 9(2):197\u2013210. https:\/\/doi.org\/10.14283\/jpad.2022.30","journal-title":"J Prev Alzheimers Dis"},{"issue":"4","key":"9430_CR11","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1312889","volume":"370","author":"RS Doody","year":"2014","unstructured":"Doody RS et al (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease. N Engl J Med 370(4):311\u2013321. https:\/\/doi.org\/10.1056\/NEJMoa1312889","journal-title":"N Engl J Med"},{"issue":"6","key":"9430_CR12","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR et al (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330(6):512\u2013527. https:\/\/doi.org\/10.1001\/jama.2023.13239","journal-title":"JAMA"},{"issue":"8","key":"9430_CR13","doi-asserted-by":"publisher","first-page":"e213483","DOI":"10.1212\/WNL.0000000000213483","volume":"104","author":"SY Jeong","year":"2025","unstructured":"Jeong SY et al (2025) Incidence of amyloid-related imaging abnormalities in phase III clinical trials of anti-amyloid-\u03b2 immunotherapy: an updated meta-analysis. Neurology 104(8):e213483. https:\/\/doi.org\/10.1212\/WNL.0000000000213483","journal-title":"Neurology"},{"key":"9430_CR14","doi-asserted-by":"publisher","first-page":"1326784","DOI":"10.3389\/fnins.2024.1326784","volume":"18","author":"SJ Doran","year":"2024","unstructured":"Doran SJ, Sawyer RP (2024) Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications. Front Neurosci 18:1326784. https:\/\/doi.org\/10.3389\/fnins.2024.1326784","journal-title":"Front Neurosci"},{"issue":"3","key":"9430_CR15","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(12)70015-7","volume":"11","author":"R Sperling","year":"2012","unstructured":"Sperling R et al (2012) Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 11(3):241\u20139. https:\/\/doi.org\/10.1016\/S1474-4422(12)70015-7","journal-title":"Lancet Neurol"},{"issue":"6","key":"9430_CR16","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR et al (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330(6):512\u2013527. https:\/\/doi.org\/10.1001\/jama.2023.13239","journal-title":"JAMA"},{"key":"9430_CR17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jclinepi.2021.02.003","volume":"134","author":"MJ Page","year":"2021","unstructured":"Page MJ et al (2021) Updating guidance for reporting systematic reviews: development of the PRISMA 2020 statement. J Clin Epidemiol 134:103\u2013112. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.02.003","journal-title":"J Clin Epidemiol"},{"key":"9430_CR18","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clinical Research ed.) 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ (Clinical Research ed.)"},{"issue":"5","key":"9430_CR19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","volume":"82","author":"JA Zimmer","year":"2025","unstructured":"Zimmer JA et al (2025) Amyloid-related imaging abnormalities with donanemab in early symptomatic Alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials. JAMA Neurol 82(5):461\u2013469. https:\/\/doi.org\/10.1001\/jamaneurol.2025.0065","journal-title":"JAMA Neurol"},{"issue":"1","key":"9430_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway S et al (2022) Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol 79(1):13\u201321. https:\/\/doi.org\/10.1001\/jamaneurol.2021.4161","journal-title":"JAMA Neurol"},{"issue":"3","key":"9430_CR21","doi-asserted-by":"publisher","first-page":"e207919","DOI":"10.1212\/WNL.0000000000207919","volume":"102","author":"SJ Loomis","year":"2024","unstructured":"Loomis SJ et al (2024) Genome-wide association studies of ARIA from the aducanumab phase 3 ENGAGE and EMERGE studies. Neurology 102(3):e207919. https:\/\/doi.org\/10.1212\/WNL.0000000000207919","journal-title":"Neurology"},{"issue":"4","key":"9430_CR22","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3233\/JAD-180675","volume":"66","author":"HR Brashear","year":"2018","unstructured":"Brashear HR et al (2018) Clinical evaluation of amyloid-related imaging abnormalities in Bapineuzumab phase III studies. J Alzheimer\u2019s Dis: JAD 66(4):1409\u20131424. https:\/\/doi.org\/10.3233\/JAD-180675","journal-title":"J Alzheimer's Dis: JAD"},{"issue":"1","key":"9430_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13195-016-0189-7","volume":"8","author":"R Vandenberghe","year":"2016","unstructured":"Vandenberghe R et al (2016) Bapineuzumab for mild to moderate Alzheimer\u2019s disease in two global, randomized, phase 3 trials. Alzheimers Res Ther 8(1):18. https:\/\/doi.org\/10.1186\/s13195-016-0189-7","journal-title":"Alzheimers Res Ther"},{"issue":"11","key":"9430_CR24","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1001\/jamaneurol.2022.2909","volume":"79","author":"S Ostrowitzki","year":"2022","unstructured":"Ostrowitzki S et al (2022) Evaluating the safety and efficacy of Crenezumab vs Placebo in adults with early Alzheimer disease: two phase 3 randomized placebo-controlled trials. JAMA Neurol 79(11):1113\u20131121. https:\/\/doi.org\/10.1001\/jamaneurol.2022.2909","journal-title":"JAMA Neurol"},{"issue":"4","key":"9430_CR25","doi-asserted-by":"publisher","first-page":"e70062","DOI":"10.1002\/alz.70062","volume":"21","author":"H Wang","year":"2025","unstructured":"Wang H et al (2025) Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction. Alzheimer\u2019s Dementia: J Alzheimer\u2019s Assoc 21(4):e70062. https:\/\/doi.org\/10.1002\/alz.70062","journal-title":"Alzheimer's Dementia: J Alzheimer's Assoc"},{"issue":"8","key":"9430_CR26","doi-asserted-by":"publisher","first-page":"100266","DOI":"10.1016\/j.tjpad.2025.100266","volume":"12","author":"H Wang","year":"2025","unstructured":"Wang H et al (2025) The effect of modified donanemab titration on amyloid-related imaging abnormalities with edema\/effusions and amyloid reduction: 18-month results from TRAILBLAZER-ALZ 6. J Prevent Alzheimer\u2019s Dis 12(8):100266. https:\/\/doi.org\/10.1016\/j.tjpad.2025.100266","journal-title":"J Prevent Alzheimer's Dis"},{"issue":"20","key":"9430_CR27","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","volume":"389","author":"RJ Bateman","year":"2023","unstructured":"Bateman RJ et al (2023) Two phase 3 trials of gantenerumab in early Alzheimer\u2019s disease. N Engl J Med 389(20):1862\u20131876. https:\/\/doi.org\/10.1056\/NEJMoa2304430","journal-title":"N Engl J Med"},{"issue":"1","key":"9430_CR28","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/jamaneurol.2024.3937","volume":"82","author":"S Salloway","year":"2025","unstructured":"Salloway S et al (2025) Amyloid-related imaging abnormalities (ARIA) in clinical trials of Gantenerumab in early Alzheimer disease. JAMA Neurol 82(1):19\u201329. https:\/\/doi.org\/10.1001\/jamaneurol.2024.3937","journal-title":"JAMA Neurol"},{"issue":"1","key":"9430_CR29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","volume":"9","author":"S Ostrowitzki","year":"2017","unstructured":"Ostrowitzki S et al (2017) A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease. Alzheimer\u2019s Res Ther 9(1):95. https:\/\/doi.org\/10.1186\/s13195-017-0318-y","journal-title":"Alzheimer's Res Ther"},{"issue":"7","key":"9430_CR30","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","volume":"27","author":"S Salloway","year":"2021","unstructured":"Salloway S et al (2021) A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease. Nat Med 27(7):1187\u20131196. https:\/\/doi.org\/10.1038\/s41591-021-01369-8","journal-title":"Nat Med"},{"issue":"1","key":"9430_CR31","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH et al (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"issue":"1","key":"9430_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01441-8","volume":"16","author":"LS Honig","year":"2024","unstructured":"Honig LS et al (2024) Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s disease. Alzheimers Res Ther 16(1):105. https:\/\/doi.org\/10.1186\/s13195-024-01441-8","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"9430_CR33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"LS Honig","year":"2018","unstructured":"Honig LS et al (2018) Trial of Solanezumab for mild dementia due to Alzheimer\u2019s disease. New England J Med 378(4):321\u2013330. https:\/\/doi.org\/10.1056\/NEJMoa1705971","journal-title":"New England J Med"},{"issue":"10","key":"9430_CR34","doi-asserted-by":"publisher","first-page":"e70751","DOI":"10.1002\/alz.70751","volume":"21","author":"Z Shirzadi","year":"2025","unstructured":"Shirzadi Z et al (2025) Independent effects of white matter lesion volume and APOE \u025b4 on ARIA-H in A4 Study. Alzheimer\u2019s Dementia: J Alzheimer\u2019s Assoc 21(10):e70751. https:\/\/doi.org\/10.1002\/alz.70751","journal-title":"Alzheimer's Dementia: J Alzheimer's Assoc"},{"issue":"4","key":"9430_CR35","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1056\/NEJMoa1304839","volume":"370","author":"S Salloway","year":"2014","unstructured":"Salloway S et al (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer\u2019s disease. New England J Med 370(4):322\u201333. https:\/\/doi.org\/10.1056\/NEJMoa1304839","journal-title":"New England J Med"},{"key":"9430_CR36","doi-asserted-by":"publisher","first-page":"P251","DOI":"10.1016\/j.jalz.2017.06.111","volume":"13","author":"CD Carlson","year":"2017","unstructured":"Carlson CD et al (2017) Safety of solanezumab in phase 3 studies in individuals with mild Alzheimer\u2019s disease dementia. Alzheimers Dement 13:P251\u2013P252. https:\/\/doi.org\/10.1016\/j.jalz.2017.06.111","journal-title":"Alzheimers Dement"},{"issue":"8","key":"9430_CR37","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.3174\/ajnr.A3475","volume":"34","author":"F Barkhof","year":"2013","unstructured":"Barkhof F et al (2013) An MRI rating scale for amyloid-related imaging abnormalities with edema or effusion. AJNR Am J Neuroradiol 34(8):1550\u20131555. https:\/\/doi.org\/10.3174\/ajnr.A3475","journal-title":"AJNR Am J Neuroradiol"},{"issue":"1","key":"9430_CR38","doi-asserted-by":"publisher","first-page":"e12376","DOI":"10.1002\/dad2.12376","volume":"14","author":"G Klein","year":"2022","unstructured":"Klein G et al (2022) Comparing ARIA-E severity scales and effects of treatment management thresholds. Alzheimer\u2019s Dementia (Amsterdam, Netherlands) 14(1):e12376. https:\/\/doi.org\/10.1002\/dad2.12376","journal-title":"Alzheimer's Dementia (Amsterdam, Netherlands)"},{"issue":"19","key":"9430_CR39","doi-asserted-by":"publisher","first-page":"e2092","DOI":"10.1212\/WNL.0000000000201019","volume":"99","author":"SY Jeong","year":"2022","unstructured":"Jeong SY et al (2022) Incidence of amyloid-related imaging abnormalities in patients with Alzheimer disease treated with anti-\u03b2-Amyloid immunotherapy: a meta-analysis. Neurology 99(19):e2092\u2013e2101. https:\/\/doi.org\/10.1212\/WNL.0000000000201019","journal-title":"Neurology"},{"issue":"5","key":"9430_CR40","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/EDE.0000000000001232","volume":"31","author":"L Lin","year":"2020","unstructured":"Lin L, Chu H (2020) Meta-analysis of proportions using generalized linear mixed models. Epidemiology (Cambridge, Mass.) 31(5):713\u2013717. https:\/\/doi.org\/10.1097\/EDE.0000000000001232","journal-title":"Epidemiology (Cambridge, Mass.)"},{"key":"9430_CR41","doi-asserted-by":"publisher","DOI":"10.2174\/011570159X391766250806091602","author":"D An","year":"2025","unstructured":"An D et al (2025) Structural and functional determinants of ARIA-H risk in anti-amyloid monoclonal antibodies: a comparative mechanistic framework for Alzheimer\u2019s immunotherapy development. Curr Neuropharmacol. https:\/\/doi.org\/10.2174\/011570159X391766250806091602","journal-title":"Curr Neuropharmacol"},{"key":"9430_CR42","doi-asserted-by":"publisher","first-page":"1632252","DOI":"10.3389\/fnagi.2025.1632252","volume":"17","author":"NM Noto","year":"2025","unstructured":"Noto NM et al (2025) Cerebral amyloid angiopathy: a narrative review. Front Aging Neurosci 17:1632252. https:\/\/doi.org\/10.3389\/fnagi.2025.1632252","journal-title":"Front Aging Neurosci"},{"issue":"7","key":"9430_CR43","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1001\/jamaneurol.2025.1232","volume":"82","author":"M Paczynski","year":"2025","unstructured":"Paczynski M et al (2025) Lecanemab treatment in a specialty memory clinic. JAMA Neurol 82(7):655\u2013665. https:\/\/doi.org\/10.1001\/jamaneurol.2025.1232","journal-title":"JAMA Neurol"},{"issue":"3","key":"9430_CR44","first-page":"320","volume":"112","author":"M Adelman","year":"2025","unstructured":"Adelman M, Hull ML (2025) Donanemab (Kisunla) for the slowing of Alzheimer disease. Am Family Phys 112(3):320\u2013321","journal-title":"Am Family Phys"},{"issue":"3","key":"9430_CR45","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1177\/13872877251404505","volume":"109","author":"A VillarejoGalende","year":"2026","unstructured":"VillarejoGalende A et al (2026) Severe symptomatic amyloid-related imaging abnormalities in Alzheimer\u2019s disease: two case reports and systematic review of reported cases. J Alzheimers Dis 109(3):1099\u20131116. https:\/\/doi.org\/10.1177\/13872877251404505","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"9430_CR46","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/ana.21953","volume":"67","author":"P Vemuri","year":"2010","unstructured":"Vemuri P et al (2010) Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol 67(3):308\u201316. https:\/\/doi.org\/10.1002\/ana.21953","journal-title":"Ann Neurol"},{"issue":"7806","key":"9430_CR47","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","volume":"581","author":"A Montagne","year":"2020","unstructured":"Montagne A et al (2020) APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Nature 581(7806):71\u201376. https:\/\/doi.org\/10.1038\/s41586-020-2247-3","journal-title":"Nature"},{"issue":"1","key":"9430_CR48","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S1474-4422(20)30412-9","volume":"20","author":"A Serrano-Pozo","year":"2021","unstructured":"Serrano-Pozo A et al (2021) APOE and Alzheimer\u2019s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol 20(1):68\u201380. https:\/\/doi.org\/10.1016\/S1474-4422(20)30412-9","journal-title":"Lancet Neurol"},{"issue":"10","key":"9430_CR49","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1093\/brain\/awac257","volume":"145","author":"KB Casaletto","year":"2022","unstructured":"Casaletto KB et al (2022) Sex-specific effects of microglial activation on Alzheimer\u2019s disease proteinopathy in older adults. Brain\u202f: J Neurol 145(10):3536\u20133545. https:\/\/doi.org\/10.1093\/brain\/awac257","journal-title":"Brain : J Neurol"},{"issue":"5","key":"9430_CR50","doi-asserted-by":"publisher","first-page":"e70304","DOI":"10.1002\/alz.70304","volume":"21","author":"M Abu Raya","year":"2025","unstructured":"Abu Raya M et al (2025) Sex differences in amyloid PET in a large, real-world sample from the Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) study. Alzheimer\u2019s & Dementia: J Alzheimer\u2019s Assoc 21(5):e70304. https:\/\/doi.org\/10.1002\/alz.70304","journal-title":"Alzheimer's & Dementia: J Alzheimer's Assoc"},{"issue":"21","key":"9430_CR51","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12216792","volume":"12","author":"M-K Sin","year":"2023","unstructured":"Sin M-K et al (2023) \u201cAnti-amyloid therapy, AD, and ARIA: untangling the role of CAA.\u201d J Clin Med 12(21):6792. https:\/\/doi.org\/10.3390\/jcm12216792","journal-title":"J Clin Med"},{"issue":"19","key":"9430_CR52","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1212\/WNL.0000000000207757","volume":"101","author":"VK Ramanan","year":"2023","unstructured":"Ramanan VK et al (2023) Antiamyloid monoclonal antibody therapy for Alzheimer disease: emerging issues in neurology. Neurology 101(19):842\u2013852. https:\/\/doi.org\/10.1212\/WNL.0000000000207757","journal-title":"Neurology"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09430-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09430-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09430-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:02:54Z","timestamp":1793671374000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09430-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["9430"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09430-5","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study is based exclusively on previously published data and no primary data collection involving human subjects was performed.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"In compliance with ethical standards, Authors declare that there is not any conflict of interest to declare.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"CRD420251274032.","order":3,"name":"Ethics","label":"Registry and the registration No. of the study\/trial","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"835"}}